Spero Therapeutics, Inc.SPRONASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
5Y CAGR+10.1%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
+10.1%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
1.6x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$108.24M+11.9%
2024$96.76M+88.1%
2023$51.44M-
2022$0.00-
2021$0.00-100.0%
2020$67.00M+1.9%
2019$65.78M+94.1%
2018$33.88M+3.1%
2017$32.87M+24.8%
2016$26.33M-